Home » News » Conference Coverage » American Society of Hematology (ASH) » ASH 2020 » ASH 2020 CLL In-depth
ASH 2020 CLL In-depth
Complete Coverage Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.
Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.
The combination was also associated with improvements in progression-free and overall survival.
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Load More
Want to read more?
Please login or register first to view this content.
Login
Register
Open
Next post in ASH 2020 CLL In-depth
Close